Abstract
In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 676-685 |
| Number of pages | 10 |
| Journal | Cancer Research |
| Volume | 72 |
| Issue number | 3 |
| DOIs | |
| State | Published - Feb 1 2012 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. / Lu, Beibei; Viscidi, Raphael P; Wu, Yougui; Lee, Ji Hyun; Nyitray, Alan G.; Villa, Luisa L.; Lazcano-Ponce, Eduardo; Carvalho Da Silva, Roberto J.; Baggio, Maria Luiza; Quiterio, Manuel; Salmeron, Jorge; Smith, Danelle C.; Abrahamsen, Martha E.; Papenfuss, Mary R.; Stockwell, Heather G.; Giuliano, Anna R.
In: Cancer Research, Vol. 72, No. 3, 01.02.2012, p. 676-685.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men
AU - Lu, Beibei
AU - Viscidi, Raphael P
AU - Wu, Yougui
AU - Lee, Ji Hyun
AU - Nyitray, Alan G.
AU - Villa, Luisa L.
AU - Lazcano-Ponce, Eduardo
AU - Carvalho Da Silva, Roberto J.
AU - Baggio, Maria Luiza
AU - Quiterio, Manuel
AU - Salmeron, Jorge
AU - Smith, Danelle C.
AU - Abrahamsen, Martha E.
AU - Papenfuss, Mary R.
AU - Stockwell, Heather G.
AU - Giuliano, Anna R.
PY - 2012/2/1
Y1 - 2012/2/1
N2 - In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.
AB - In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.
UR - http://www.scopus.com/inward/record.url?scp=84863072028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863072028&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-11-0751
DO - 10.1158/0008-5472.CAN-11-0751
M3 - Article
C2 - 22123925
AN - SCOPUS:84863072028
VL - 72
SP - 676
EP - 685
JO - Journal of Cancer Research
JF - Journal of Cancer Research
SN - 0099-7013
IS - 3
ER -